A Comparative Study of the Effects of Low-Dose Topiramate Versus Sodium Valproate in Migraine Prophylaxis

REFERENCES

• Hamalainen ML. Migraine in children and adolescents: a guide to drug treatment. CNS Drugs. 2006;20:813–20.
   PubMedGoogle Scholar
• Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9.
   PubMed Web of Science ®Google Scholar
• Buchanan TM, Ramadan NM. Prophylactic pharmacotherapy for migraine headaches. Semin Neurol. 2006;26:188–98.
   PubMedGoogle Scholar
• Diener HC, Limmroth V. Migraine therapy. Internist (Berl). 2005;46:1087–95.
   PubMedGoogle Scholar
• Mathew NT, Saper JR, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapoport AM, Silber CJ, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281–86.
   PubMed Web of Science ®Google Scholar
• Klapper J. Divalprex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103–08.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Rapoport A, Saper J. Efficacy of gabapentin in migraine prophylaxis. Headache 2001;41:119–28.
   PubMed Web of Science ®Google Scholar
• Freitag FG, Collins SD, Carlson HA. A randomized trial of divalproex sodium extended release tablets in migraine prophylaxis. Neurology 2002;58:1652–59.
   PubMed Web of Science ®Google Scholar
• D'Amico D, Grazzi L, Usai S, Moschiano F, Bussone G. Topiramate in migraine prophylaxis. Neurol Sci. 2005;26(Suppl. 2):s130–3.
   Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004;61:490–5.
   PubMed Web of Science ®Google Scholar
• White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005;45:s48–56.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double blind, placebo-controlled trial. Headache 2007;47:170–80.
   PubMed Web of Science ®Google Scholar
• Edwards KR, Potter DL, Wu SC, Kamin M, Hulihan J. Topiramate in the preventive treatment of episodic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectr. 2003;8(6):428–32.
   PubMed Web of Science ®Google Scholar
• Brandes JL, Saper JR, Diamond M. Topiramate for migraine prevention: a randomized controlled trial. JAMA. 2004;291:965–73.
   PubMed Web of Science ®Google Scholar
• Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45(Suppl. 1):S66–73.
   PubMedGoogle Scholar
• Huppertz HJ, Quiske A, Schulze-Bonhage A. Cognitive impairments due to add-on therapy with topiramate. Nervenarzt 2001;72:275–80.
   Google Scholar
• Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand. 2008;118(5):301–5.
   PubMedGoogle Scholar
• Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46(4):642–8.
   PubMedGoogle Scholar
• Hashemi J, Kheirabadi G, Movahedian A. Lithium ratio in bipolar patients in Isfahan, Iran. J Res Med Sci. 2006;11(4): 257–262.
   Google Scholar
• Mohebbi A, Honarvar M, Behzadi A. Time trend in outpatient warfarin therapy based on international normalization ratio. Iranian Heart J. 2008;9(3):37–41.
   Google Scholar
• The International Classification of Headache Disorders. 2nd ed. Headache Classification Subcommittee of the International Headache Society. Cephalagia (Oxford, England, UK: Blackwell Publishing) 24(1): 1–160.
   Google Scholar
• Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41(10):968–75.
   PubMed Web of Science ®Google Scholar
• Mei D, Capuano A, Vollono C, Evangelista M, Ferraro D, Tonali P, Di Trapani G. Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. Neurol Sci. 2004;25(5):245–50.
   PubMedGoogle Scholar
• Bavrasad R, Nejad SEM, Yarahmadi AR, Sajedi SI, Rahimi F. Assessment of the middle dose of topiramate in comparison with sodium valproate for migraine prophylaxis: a randomized double blind study. Science Alert. 2010;670–5
   Google Scholar
• Winner P, Gendolla A, Stayer C, Wang S, Yuen E, Battisti WP, Nye JS; Topiramate for migraine prevention in adolescents: a pooled analysis of efficacy and safety. Headache 2006;46(10):1503–10.
   PubMedGoogle Scholar
• Bartolini M, Silvestrini M, Taffi R, Lanciotti C, Luconi R, Capecci M, Provinciali L. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol. 2005;28(6):277–9.
   PubMedGoogle Scholar
• Lo YL, Lum SY, Fook-Chang S, Siow HC. A pilot study of topiramate dosage for migraine prophylaxis in an Asian population. Headache Pain. 2010;11:175–8.
   PubMed Web of Science ®Google Scholar
• Gupta P, Singh S, Goyal V, Shukla G, Behari M. Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache 2007;47(3):402–12.
   PubMed Web of Science ®Google Scholar
• Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23(8):820–4.
   PubMedGoogle Scholar